NC

VA-CEDAR Tool for Equity in Lung Cancer Screening

Neelima Navuluri, MD, MPH
Durham VA Medical Center
Durham

The veteran population is disproportionately affected by lung cancer and relatively few patients that are eligible participate in lung cancer screening. This low participation is due to barriers such as provider bias, structural racism, patient mistrust, and fear of diagnosis. In this project, Dr. Navuluri proposes to develop and test an electronic shared decision-making aid and referral tool to improve equity in lung cancer screening (LCS).  She will pilot test the aid to assess its feasibility and usability among patients and providers within the Durham VA system.

Key words

Discovery of novel artificial transcription factors regulating lung cancer cell invasion and progression

Funded equally by LUNGevity Foundation and American Lung Association National Office
Pilar Blancafort, PhD
University of North Carolina at Chapel Hill
Chapel Hill

Transcription factors are specialized proteins that translate the DNA footprint of cells to make RNA, which eventually helps to make proteins. Dr. Blancafort plans to use artificial transcription factors (ATFs) to identify and regulate genes involved in lung cancer disease progression. This research will lead to the identification of new markers of progression that could be used as early predictors of lung cancer.

Targeting NF-KappaB as a new treatment for lung cancer

Funded equally by LUNGevity Foundation and the National Lung Cancer Partnership
Albert S. Baldwin, PhD
Lineberger Cancer Center, The University of North Carolina at Chapel Hill
Chapel Hill

Dr. Baldwin is identifying and testing new therapeutic targets for KRAS-positive lung cancer. KRAS activates the factor NF-κβ, which, when abnormally active, can contribute to the growth of lung tumors. This activation involves two kinases, and well-validated inhibitors of these pathways exist. This project is determining whether these inhibitors will block the initiation and/or progression of lung tumors.

Heterogeneity of Microarray-based Lung Cancer Signature in Patients with Lung Cancer

Funded by LUNGevity Foundation and The CHEST Foundation
Scott L. Shofer, MD
Durham VA Medical Center Pulmonary Service
Durham

Dr. Shofer’s research builds on work of earlier investigators who developed a lung cancer risk signature based on genetic changes in lung cells in smokers. Dr. Shofer hypothesizes that the lung cancer risk signature model is an indicator of how lung cells change during the process of cancer development. Should his hypothesis be correct, the lung cancer risk signature could be established as a sensitive biomarker capable of diagnosing patients with lung cancer by checking cells taken from the throat using a swab.

Analysis of Lung Adenocarcinoma Heterogeneity Based Upon Cell-of-Origin

National Lung Cancer Partnership/LUNGevity Foundation Research Grant
Mark W. Onaitis, MD
Duke University
Durham

The KRAS gene is the most common mutation in non-small cell lung cancer. Dr. Onaitis is studying how mutations of the KRAS gene affect different types of cells in the lungs and how these differences can be used to develop a targeted therapy that can lessen the effects of KRAS in lung cancer cells.

Serum Biomarkers for the Early Detection of Lung Cancer

This grant was funded in part by Thomas G. Labrecque Foundation
Edward Patz, MD
Duke University Medical Center
Durham
Michael Campa, PhD
Duke University Medical Center
Durham
NC
James Herndon
Duke University Medical Center
Durham
NC

CT scans often detect the presence of a lung nodule. Most of these nodules are benign. Dr. Edward Patz and his colleagues have discovered 25 auto-antibodies (protein molecules) found in the blood of non-small cell lung cancer patients. They are developing a simple, blood-based test to confirm these findings in larger groups of these patients.